|Author||: Benjamin Bonavida|
|Publisher||: Academic Press|
|Release Date||: 2020-11-02|
|ISBN 10||: 0128226366|
|Pages||: 360 pages|
YY1 Is Pivotal in the Control of the Pathogenesis and Drug Resistance of Cancer: A Critical Therapeutic Target describes the current state-of-the-art of the transcription factor YY1 that is overexpressed in the majority of cancers and a central factor that regulates all of the major features and characteristics of human cancers. This book emphasizes the biochemical, molecular and genetic underlying mechanisms by which YY1 regulates its pro-cancerous activities. In addition, it also describes the role of YY1 in the regulation of tumor cell resistance to conventional chemo and immunotherapies and the important role of inhibiting YY1 in cancer. This book is a valuable source for cancer researchers, oncologists and several members of medical and biomedical field who are interested in understanding further the role of YY1 in cancer. Provides a thorough understanding of the underlying mechanisms by which YY1 regulates cancer cell phenotype and unique characteristics Discusses the novel mechanisms of YY1 regulation of tumor cell resistance and means to overcome resistance Encompasses new examples of newly developed non-toxic and selective inhibitors targeting YY1
|Author||: Benjamin Bonavida|
|Publisher||: Springer Science & Business Media|
|Release Date||: 2008-07-31|
|ISBN 10||: 9781597454742|
|Pages||: 420 pages|
This book reviews novel approaches developed to reverse tumor cell resistance to chemo/immuno/radio-therapy and the use of various sensitizing agents in combination with various cytotoxics. It also introduces several current approaches developed by established investigators that are aimed at overcoming resistance. This is the first volume to compile studies on tumor cell sensitization. It will prove useful for students, scientists, clinicians and pharmaceutical companies.
|Author||: Benjamin Bonavida,Stavroula Baritaki|
|Publisher||: Academic Press|
|Release Date||: 2020-03-02|
|ISBN 10||: 0128196122|
|Pages||: 504 pages|
Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students. Provides an update from experts in the field on diagnostics, prognostics and therapeutics Brings a clear overview of recent findings and references, as well as summaries, significant molecular pathways, and conclusions in each chapter Provides a general introductory chapter on contributions in the field and a chapter summary, with synthesized findings and a projection of future goals
The collection of chapters in this proceeding volume reflects the latest research presented at the Aegean meeting on Tumor Microenvironment and Cellular Stress held in Crete in Fall of 2012. The book provides critical insight to how the tumor microenvironment affects tumor metabolism, cell stemness, cell viability, genomic instability and more. Additional topics include identifying common pathways that are potential candidates for therapeutic intervention, which will stimulate collaboration between groups that are more focused on elucidation of biochemical aspects of stress biology and groups that study the pathophysiological aspects of stress pathways or engaged in drug discovery.
|Author||: Myron R. Szewczuk,Bessi Qorri,Manpreet Sambi|
|Release Date||: 2019-07-15|
|ISBN 10||: 303021477X|
|Pages||: 320 pages|
Targeted therapies were initially developed to exploit the upregulation and dependence on key oncogenic pathways critical to cancer progression. Additionally, they also presented as a method to overcome chemoresistance by supplementing conventional therapeutic regimens with targeted therapies. However, the development of resistance to these combinatorial approaches has led to the reassessment of currently available therapeutic options to overcome resistance to targeted therapy. This book aims to provide an update on the advancements in the therapeutic arms race between cancer, clinicians and scientists alike to overcome resistance to targeted therapies. Subject experts provide a comprehensive overview of the challenges and solutions to resistance to several conventional targeted therapies in addition to providing a discussion on broad topics including targeting components of the tumor microenvironment, emerging therapeutic options, and novel areas to be explored concerning nanotechnology and the epigenome.
Molecular Therapies of Cancer comprehensively covers the molecular mechanisms of anti-cancer drug actions in a comparably systematic fashion. While there is currently available a great deal of literature on anti-cancer drugs, books on the subject are often concoctions of invited review articles superficially connected to one another. There is a lack of comprehensive and systematic text on the topic of molecular therapies in cancer. A further deficit in the relevant literature is a progressive sub-specialization that typically limits textbooks on cancer drugs to cover either pharmacology or medicinal chemistry or signal transduction, rather than explaining molecular drug actions across all those areas; Molecular Therapies of Cancer fills this void. The book is divided into five sections: 1. Molecular Targeting of Cancer Cells; 2. Emerging and Alternative Treatment Modalities; 3. Molecular Targeting of Tumor-Host Interactions; 4. Anti-Cancer Drug Pharmacokinetics; and 5. Supportive Therapies.
Metastasis of cancer cells from primary tumor site to secondary locations is considered a late event in multistep tumorigenesis, and causes most cancer-related mortality. The process from the spreading of cancer cells to the seeding of newly formed tumor colonizations is governed by sequential events, including local invasion, intravasation into stroma and blood vessels, survival in circulation, extravasation, and colonization at secondary tumor sites. Cancer research provides information on the fate of metastatic cancer cells in each sequential movement or heterogeneous tumor microenvironment. However, the complexity of this mechanism remains the most stringent concept of cancer management. This book provides information for cancer researchers on metastatic phenotypes of cancer cells, and diverse promoting factors and molecular mechanisms of metastasis.
This book focuses on the context dependency of cell signaling by showing how the endosomal system helps to structure and regulate signaling pathways. The location and concentration of signaling nodes regulate their activation cycles and engagement with distinct effector pathways. Whilst many cell signaling pathways are initiated from the cell surface, endocytosis provides an opportunity for modulating signaling networks’ output. In this book, first a series of reviews describe the endocytic and endosomal system and show how these subcellular platforms sort and regulate a wide range of signaling pathway components and phenotypic outputs. The book then reviews the latest scientific insights into how endocytic trafficking and subcellular location modulate a set of major pathways that are essential to normal cellular function and organisms’ development.
This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.
In the post human-genome project era, cancer specific genomic maps are redesigning tumor taxonomy by evolving from histopathology to molecular pathology. The success of a cancer drug today is fundamentally based on the success in identifying target genes that control beneficial pathways. The overwhelming power of genomics and proteomics has enlightened researchers about the fact that the PI3K-mTOR pathway is the most commonly up-regulated signal transduction pathway in various cancers, either by virtue of its activation downstream of many cell surface growth factor receptors or by virtue of its collateral and compensatory circuitry with RAS-MAPK pathway. Oncogenic signaling in the majority of solid tumors is sustained via the PI3K-AKT-mTOR pathway. Because of its prominent role in many cancer types, the PI3K-mTOR pathway has become a major therapeutic target. The volume includes two complementary parts which address the problem of etiology and disease progression and is intended to portray the very basic mechanisms of the PI3K-AKT-mTOR signaling pathway’s involvement in various facets of the cancer, including stem cell renewal, cell metabolism, angiogenesis, genetic instability, and drug resistance. Significant progress has been made in recent years elucidating the molecular mechanism of cancer cell proliferation, angiogenesis, and drug-resistance in relation to the PI3K-mTOR pathway and this volume provides an in-depth overview of recent developments made in this area.
This book focuses on malignant melanoma, discussing the current state of scientific knowledge and providing insights into the underlying basic mechanisms, the molecular changes, genetics and genomics. Human Melanoma is a dangerous type of skin cancer affecting an increasing population, and a better understanding of its development will help in finding sophisticated targeted therapies. The second revised edition features the latest research findings and offers updates on the latest advances and potential novel melanoma therapies. It is a valuable resource for researchers and clinicians working in the fields of melanoma, cancer research and therapy as well as dermatology.
With the explosion of information on autophagy in cancer, this is an opportune time to speed the efforts to translate our current knowledge about autophagy regulation into better understanding of its role in cancer. This book will cover the latest advances in this area from the basics, such as the molecular machinery for autophagy induction and regulation, up to the current areas of interest such as modulation of autophagy and drug discovery for cancer prevention and treatment. The text will include an explanation on how autophagy can function in both oncogenesis and tumor suppression and a description of its function in tumor development and tumor suppression through its roles in cell survival, cell death, cell growth as well as its influences on inflammation, immunity, DNA damage, oxidative stress, tumor microenvironment, etc. The remaining chapters will cover topics on autophagy and cancer therapy. These pages will serve as a description on how the pro-survival function of autophagy may help cancer cells resist chemotherapy and radiation treatment as well as how the pro-death functions of autophagy may enhance cell death in response to cancer therapy, and how to target autophagy for cancer prevention and therapy − what to target and how to target it.
|Author||: Karel Pacak,David Taïeb|
|Publisher||: Humana Press|
|Release Date||: 2016-12-26|
|ISBN 10||: 3319460382|
|Pages||: 484 pages|
Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles. Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.
Epigenetics and Dermatology explores the role of epigenetics in the pathogenesis of autoimmune-related skin diseases and skin cancer. Leading contributors cover common and uncommon skin conditions in which extensive epigenetic research has been done. They explain how environmental exposures (chemicals, drugs, sunlight, diet, stress, smoking, infection, etc.) in all stages of life (from a fetus in-utero to an elderly person) may result in epigenetic changes that lead to development of some skin diseases in life. They also discuss the possibilities of new and emergent epigenetic treatments which are gradually being adopted in management of various skin diseases. Chapters follow a conventional structure, covering fundamental biology of the disease condition, etiology and pathogenesis, diagnosis, commonly available treatments, and epigenetic therapy where applicable. Discusses the basic biology of skin diseases and skin cancers induced or aggravated by aberrant epigenetic changes Evaluates how to approach autoimmune-related skin diseases from a therapeutic perspective using the wealth of emergent epigenetic clinical trials Offers a coherent and structured table of contents with basic epigenetic biology followed by discussion of the spectrum of rheumatologic through neoplastic skin diseases, finally ending with a discourse on epigenetic therapy
This new volume in the Current topics in Developmental Biology series concentrates on MicroRNAs in Development. It includes chapters on such topics as miRNA networks in neuronal development, let-7 in development, and Hox networks and miRNA. With an international team of authors, this volume is a must-have addition for researchers and students alike. Concentrates on microRNAs in development Includes chapters on such topics as miRNA networks in neuronal development, let-7 in development, and Hox networks and miRNA With an international team of authors, this volume is a must-have addition for researchers and students alike
|Author||: Andrés J. M. Ferreri|
|Release Date||: 2018-04-04|
|ISBN 10||: 3319751840|
|Pages||: 138 pages|
In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance.
This volume contains a unique selection of chapters covering a wealth of contemporary topics in this ubiquitous and diverse system of cell signaling. It offers much more than the accessibility and authority of a primary text book, exploring topics ranging from the fundamental aspects of calcium signaling to its varied clinical implications. It presents comprehensive discussion of cutting-edge research alongside detailed analysis of critical issues, at the same time as setting out testable hypotheses that point the way to future scientific endeavors. The contributions feature material on theoretical and methodological topics as well as related subjects including mathematical modeling and simulations. They examine calcium signaling in a host of contexts, from mammalian cells to bacteria, fruit fly and zebrafish. With much of interest to newcomers to the field as well as seasoned experts, this new publication is both wide-ranging and authoritative. The chapter “Calcium Signaling: From Basic to Bedside” is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com.
Advances in Nitric Oxide and Cancer is a volume that serves to give the latest research on nitric oxide (NO) and cancer. More specifically, the volume reviews significant advances in the application of NO-mediated drugs. The volume explores nitric oxide and its relationship to cancer spanning from its roles in the pathogenesis, prognosis, gene and protein modifications, regulation of resistance to cytotoxics, and therapeutic applications. With chapters written by leading experts, the volume addresses the burgeoning interest in a rapidly advancing field and provides a valuable resource to scientists who have initiated research as well as clinical investigations in their laboratories on the various roles of NO and cancer.
Current Advances in Osteosarcoma edited by Dr. Eugenie S. Kleinerman summarizes molecular and genetic characteristics, new therapeutic ideas, and biological characteristics that have been uncovered in the past 10 years. Osteosarcoma is an aggressive malignant neoplasm and it is also the most common histological form of bone cancer. It accounts for approximately 56% of new bone tumors, making it the most primary malignant bone tumor in children and adolescents. The lungs are the most common site of metastases and once osteosarcoma spreads to the lungs, it is very difficult to treat. To improve the outcome of this disease, the biology of osteosarcoma needs to be better understood. There are numerous investigators around the world who have made seminal discoveries about the important molecular pathways and genetic alterations that contribute to the development and metastases of osteosarcoma. Other investigators have proposed novel therapeutic strategies including some based on the molecular and genetic phenotype of the disease. Current Advances in Osteosarcoma summarizes all of these new discoveries in one singular text, which will help move the field forward.
The mammalian gastrointestinal mucosa is a rapidly self-renewing tissue in the body, and its homeostasis is preserved through the strict regulation of epithelial cell proliferation, growth arrest, and apoptosis. The control of the growth of gastrointestinal mucosa is unique and, compared with most other tissue in the body, complex. Mucosal growth is regulated by the same hormones that alter metabolism in other tissues, but the gastrointestinal mucosa also responds to host events triggered by the ingestion and presence of food within the digestive tract. These gut hormones and peptides regulate the growth of the exocrine pancreas, gallbladder epithelium, and the mucosa of the oxyntic gland region of the stomach and the small and large intestines. Luminal factors, including nutrients or other dietary factors, secretions, and microbes that occur within the lumen and distribute over a proximal-to-distal gradient, are also crucial for maintenance of normal gut mucosal regeneration and could explain the villous-height-crypt-depth gradient and variety of adaptation, since these factors are diluted, absorbed, and destroyed as they pass down the digestive tract. Recently, intestinal stem cells, cellular polyamines, and noncoding RNAs are shown to play an important role in the regulation of gastrointestinal mucosal growth under physiological and various pathological conditions. In this book, we highlight key issues and factors that control gastrointestinal mucosal growth and homeostasis, with special emphasis on the mechanisms through which epithelial renewal and apoptosis are regulated at the cellular and molecular levels.